REGENERON PHARMACEUTICALS, INC. (REGN) Earnings History

3 quarters held2/8 transcripts analyzed2/15 figures attested
Connect your agent
PeriodRevenueYoYNet incomeEPS (dil.)Filed
Q2 2026$4.3B+16.7%$1.3B$12.23Jul 30, 2026
LATESTEarnings filing (8-K)10-QFiled Jul 30, 2026, 6:48 AM ET
Earnings call · Jul 30, 2026
Q2 FY26YoY6M FY26
Revenue$4.3B1+16.7%–
Net income$1.3B-6.8%$2.0B
Op income$1.3B+19.8%$1.9B
EPS (dil.)$12.23-4.5%–
EPS (basic)$12.62-4.7%–
Gross margin78.0%-5.0pp
Op margin30.1%+0.8pp
Net margin30.2%-7.6pp
  1. [1] “Total revenues $ 4,291 $ 3,676 17 %” view source

Guidance & outlook

Management guidance

Q2 2026

fy_current

other
6.5B—6.6B
other
6.0B—6.0B
other
2.8B—3.0B
other
2.5B—2.6B
gross_margin_pct
78.0%—79.0%
gross_margin_pct
84.0%—85.0%
other
985M—1.0B
other
970M—1.0B
capex
1.0B—1.1B
other
13—14
other
14—15

Special items & operational metrics

Operational metrics

Q2 2026
Dupixent global net sales
5998.2M
+38.0% YoY
Prior year: 4344.6M
USD
EYLEA U.S. net sales
412.2M
-45.3% YoY
Prior year: 754.3M
USD
Libtayo global net sales
489.4M
+30.0% YoY
Prior year: 376.5M
USD
EYLEA HD U.S. net sales
596.3M
+51.9% YoY
Prior year: 393.2M
USD
Q1 2026$3.6B+19.0%$727.0M$6.75Apr 29, 2026
Earnings filing (8-K)10-QFiled Apr 29, 2026, 6:50 AM ET
Earnings call · Apr 29, 2026
Q1 FY26YoY
Revenue$3.6B1+19.0%
Net income$727.0M-10.1%
Op income$642.9M+8.7%
EPS (dil.)$6.75-7.2%
EPS (basic)$6.99-7.8%
Gross margin76.0%-5.0pp
Op margin17.8%-1.7pp
Net margin20.2%-6.5pp
  1. [1] “Total revenues $ 3,605 $ 3,029 19 %” view source
Q4 2025$238.0M–$845.0M$7.86Jan 30, 2026
Earnings filing (8-K)10-KFiled Jan 30, 2026, 6:51 AM ET
Earnings call · Jan 30, 2026transcriptView originalprepared remarksQ&A
Q4 FY25YoYFY25
Revenue$238.0M––
Net income$845.0M-8.0%$4.5B
Op income$879.9M-11.1%$3.6B
EPS (dil.)$7.86-2.5%–
EPS (basic)–––
Gross margin81.0%-3.0pp
Op margin22.7%-3.5pp
Net margin21.7%-2.5pp

IR event calendar

This company's IR event calendar has not been harvested yet — an empty result here does NOT mean the company has no IR events.

Filing coverage

57 filings indexed · 44,148 XBRL facts
FilingDatePeriodSectionsTables
8-K2026-07-30Q2 202690
10-Q2026-07-30–4189
8-K2026-07-06Q2 202650
8-K2026-06-17–10
10-Q2026-04-29–4185
8-K2026-04-29Q1 202690
DEF 14A2026-04-24–120
8-K2026-04-08Q1 202650
10-K2026-02-04FY 64119
8-K2026-01-30Q4 2025120

Showing the latest 10 of 57 — the full set is in the API.

Related Research

Analysis

Four Forces Are Manufacturing Regeneron's EPS Growth as Operations Decline